Challenges in studies of the genetic basis of Type 2 diabetes

Expert Review of Endocrinology and Metabolism

Volumn 2, Issue 4, 2007, Pages 451-459

  Laakso, Markku ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Genetics; Maturity onset diabetes of the young; Single nucleotide polymorphism; Type 2 diabetes

Indexed keywords

ACARBOSE; CALPAIN 10; GLUCOKINASE; GLUCOSE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; METFORMIN; NEUROGENIC DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PLACEBO; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR 7 LIKE 2; TROGLITAZONE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; CASE CONTROL STUDY; CHROMOSOME 2Q; CLINICAL TRIAL; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LINKAGE ANALYSIS; MATURITY ONSET DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 34547526962     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.2.4.451     Document Type: Review

References (77)

1. Zimmet P, Alberti KG, Shaw J. Global and societal complications of the diabetic epidemic. Nature 414, 782-787 (2001).
2. Mokdad AH, Ford ES, Browman BA et al. Diabetes trends in the US: 1990-1998. Diabetes Care 23, 1278-1283 (2000).
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004).
4. Hossain P. Kawar B, El Nahas M. Obesity and diabetes in the developing world - a growing challenge. N. Engl. J. Med. 356, 213-215 (2007).
5. Kahn CR. Insulin action, diabetogenes, and the cause of Type II diabetes. Diabetes 43, 1066-1082 (1994).
6. Kahn SE. The importance of β-cell failure for the development and progression of Type 2 diabetes. J. Clin. Endocrinal. Metab. 86, 4047-4058 (2001).
7. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and Type 2 diabetes. Nature 444, 840-846 (2006).
8. Groop LC, Tuomi T. Non-insulin dependent diabetes mellitus - a collision between thrifty genes and an affluent society. Ann. Med. 29, 37-53 (1997).
9. Meigs J, Cupples L, Wilson P. Parental transmission of Type 2 diabetes: the Framingham Offspring Study. Diabetes 49, 2201-2207 (2000).
10. Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. Diabetalogia 20, 87-93 (1981).
11. Kaprio J, Tuomilehto J, Koskenvuo M et al. Concordance for Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 35, 1060-1067 (1992).
12. Poulsen P, Kyvik KO, Vaag A, Beck-Nielsen H. Heritability of Type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance - a population-based twin study. Diabetologia 42, 139-145 (1999).
13. Medici F, Hawa M, Ianari A, Pyke DA, Leslie RD. Concordance rate for Type II diabetes mellitus in monozygotic twins: actuarial analysis. Diabetalogia 42, 146-150 (1999).
14. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 16, 157-177 (1993).
15. Fajans SS, Conn JW. Prediabetes, subclinical diabetes and latent clinical diabetes, interpretation, diagnosis and treatment. In: On the Nature and Treatment of Diabetes. Leibel DS, Wrenshall GS (Eds), Excerpta Medica, Amsterdam, Holland, 641-656 (1965).
16. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 24, 44-53 (1975).
17. Ledermann HM. Maturity-onset diabetes of the young (MODY) at least ten times more common than previously assumed? Diabetologia 38, 1482 (1995).
18. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N. Engl. J. Med. 345, 971-980 (2001).
19. Froguel P, Vaxillaire M, Sun F et al. Close linkage of glucokinase locus on chromosome 7p to early onset non-insulin-dependent diabetes mellitus. Nature 356, 162-164 (1992).
20. Yamagata K, Furuta H, Oda N et al. Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young MODY1. Nature 384, 458-460 (1996).
21. Yamagata K, Odai N, Kaisaki PJ et al. Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young MODY3. Nature 384, 455-458 (1996).
22. Horikawa Y, Iwasaki N, Hara M et al. Mutation in hepatocyte nuclear factor-1β gene (TCF2) associated with MODY. Nat. Genet. 17, 384-385 (1997).
23. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset Type-II diabetes mellitus MODY4 linked to IPF1. Nat. Genet. 17, 138-139 (1997).
24. Malecki MT, Jhala US, Antonellis A et al. Mutations in NEUROD1 are associated with the development of Type 2 diabetes mellitus. Nat. Genet. 23, 323-328 (1999).
25. Huopio H, Otonkoski T, Vauhkonen I, Reimann F, Ashcroft FM, Laakso M. A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet 361, 301-307 (2003).
26. Ballinger SW, Shoffner JM, Hedaya EV et al. Maternally transmitted diabetes and deafness associated with a 10.4 kb mitochondrial DNA deletion. Nat. Genet. 1, 11-15 (1992).
27. Van den Ouweland JM, Lemkes HH, Ruitenbeek W et al. Mutation in kmitochondrial tRNA (Leu) (UUR) gene in a large pedigree with maternally transmitted Type II diabetes and deafness. Nat. Genet. 1, 368-371 (1991).
28. Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology. Endocrin. Rev. 25, 899-918 (2004).
29. Tiffin N, Adie E, Turner F et al. Computational disease gene identification: a concert of methods prioritizes Type 2 diabetes and obesity candidate genes. Nucl. Acids Res. 34, 3067-3081 (2006).
30. Freeman H, Cox RD. Type 2 diabetes: a cocktail of genetic discovery. Hum. Mol. Genet. 15, R202-R209 (2006).
31. Horikawa Y, Oda N, Cox NJ et al. Genetic variation in the gene encoding calpain-10 is associated with Type 2 diabetes mellitus. Nat. Genet. 26, 163-175 (2000).
32. Song Y, Niu T, Manson JE, Kwiatkowski DJ, Liu S. Are variants in the CAP10 gene related to risk of Type 2 diabetes? A quantitative assessment of population and family-based association studies. Am. J. Hum. Genet. 74, 208-222 (2004).
33. Tsuchiya T, Schwarz PE, Bosque-Plata LD et al. Association of the calpain-10 gene with Type 2 diabetes in Europeans: results of pooled and meta-analyses. Mol. Genet. Metab. 89, 174-184 (2006).
34. Reynisdottir I, Thorleifsson G, Benediktsson R et al. Localisation of a susceptibility gene for Type 2 diabetes to chromosome 5q34-q35.2. Am. J. Hum. Genet. 73, 323-335 (2003).
35. Grant SFA, Thorleifsson G, Reynisdottir I et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of Type 2 diabetes. Nat. Genet. 38, 320-323 (2006).
36. Zegginni E, McCarthy MI. TCF7L2: the biggest story in diabetes genetics since HLA? Diabetologia 50, 1-4 (2007).
37. Deeb SS, Fajans L, Nemoto M et al. A Pro12A1a substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20, 284-287 (1998).
38. Altshuler D, Hirschhhorn JN, Lannermark M et al. The common PPARγ Pro12A1a polymorphism is associated with decreased risk of Type 2 diabetes. Nat. Genet. 26, 76-80 (2000).
39. Gloyn AL, Weedon MN, Owen KR et al. Large-scale association studies of variants in genes encoding the pancreatic β-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with Type 2 diabetes. Diabetes 52, 568-572 (2003).
40. Love-Gregory LD, Wasson J, Ma J et al. A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4 gene on chromosome 20q is associated with Type 2 diabetes and appears to contribute to the evidence for linkage in an Ashkenazi Jewish population. Diabetes 53, 1134-1140 (2004).
41. Silander K, Mohike KL, Scott LJ et al. Genetic variation near the hepatocyte nuclear factor-4α gene predicts susceptibility to Type 2 diabetes. Diabetes 53, 1141-1149 (2004).
42. Baroso I, Luan J, Middelberg RPS et al. Candidate gene association study in Type 2 diabetes indicates a role for genes involved in β-cell function as well as insulin action. PLoS Biology 1, 41-55 (2003).
43. Andrulionyte L, Laukkanen O, Chiasson JL, Laakso M for the STOP-NIDDM Study Group. Single nucleotide polymorphisms in the promoter of the HNF4α gene are associated with the conversion to Type 2 diabetes: the STOP-NIDDM trial. J. Mol. Med. 84, 701-708 (2006).
44. Hegele RA, Cao H, Harris SB, Hanley AJ, Zinman B. Hepatocyte nuclear factor-1α G319S. A private mutation in Oji-Cree associated with Type 2 diabetes. Diabetes Care 22, 524 (1999).
45. Holmkvist J, Cervin C, Lyssenko V et al. Common variants in HNF-1α and risk of Type 2 diabetes. Diabetologia 49, 2882-2891 (2006).
46. Rose CS, Ek J, Urhammer SA et al. A-30G>A polymorphism of the β-cell-specific glucokinase promoter associated with hyperglycemia in the general population of whites. Diabetes 54, 3026-3031 (2005).
47. Cargill M, Altshuler D, Ireland J et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 22, 231-238 (1999).
48. Miettinen, O. S. The "case-control" study: valid selection of subjects. J. Chronic Dis. 38, 543-548 (1985).
49. Bhatti, P. Sigurdson AJ. Wang SS et al. Genetic variation and willingness to participate in epidemiologic research: data from three studies. Cancer Epidemiol. Biomarkers Prev. 14, 2449-2453 (2005).
50. Manolio TA, Bailey-Wilson JE, Collins FS. Genes, environment and the value of propective cohort studies. Nat. Genet. Rev. 7, 812-820 (2006).
51. Stern MP. Diabetes and atherosclerosis. Diabetes 44, 369-374 (1995).
52. Laakso M. Diabetes and cardiovascular disease in Type 2 diabetes: challenge for treatment and prevention. J. Intern. Med. 249, 225-235 (2001).
53. Chakravarti A, Little P. Nature, nurture, and human disease. Nature 421, 412-414 (2003).
54. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343-1350 (2001).
55. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
56. Lindi VI, Uusitupa MI, Lindström J et al. for the Finnish Diabetes Prevention Study Group. Association of the Pro12Ala polymorphism in the PPAR-γ2 gene with 3-year incidence of Type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51, 2581-2586 (2002).
57. Kubaszek A, Pihlajamäki J, Komarovski V et al. Promoter polymorphims of the TNF-α (G-308A) and IL-6(C-174G) genes predict the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study. Diabetes 52, 1872-1876 (2003).
58. Siitonen N, Lindström J, Eriksson J et al. Association of a deletion/insertion polymorphism in the α2B-adrenergic receptor gene with insulin secretion and Type 2 diabetes. The Finnish Diabetes Prevention Study. Diabetologia 47, 1416-1424 (2004).
59. Todorova B, Kubaszek A, Pihlajamäki J et al. The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to Type 2 diabetes: The Finnish Diabetes Prevention Study. J. Clin. Endocrinol. Metab. 89, 2019-2023 (2004).
60. Laukkanen O, Pihlajamäki J, Lindström J et al. for the Finnish Diabetes Prevention Study Group. Polymorphisms in the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study. J. Clin. Endocrinol. Metab. 89, 6286-6290 (2004).
61. Laukkanen O, Lindström J, Eriksson J et al. for the Finnish Diabetes Prevention Study Group. Polymorphisms in the SLC2A2 (GLUT2) gene are associated with the conversion from impaired glucose tolerance to Type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 54, 2256-2260 (2005).
62. Laukkanen O, Pihlajamäki J, Lindström J et al. Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on the weight change and the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study. Diabetologia 47, 871-877 (2004).
63. Salopuro T, Pulkkinen L, Lindström J et al. for the Finnish Diabetes Prevention Study Group. Genetic variation in leptin receptor gene is associated with Type 2 diabetes and body weight: The Finnish Diabetes Prevention Study. Int. J. Obes. 29, 1245-1251 (2005).
64. Mager U, Lindi V, Lindström J et al. for the Finnish Diabetes Prevention Study. Association of the Leu72Met polymorphism of the grehlin gene with the risk of Type 2 diabetes in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study. Diabet. Med. 23, 685-689 (2006).
65. Siitonen N, Pulkkinen L, Mager U et al. Association of sequence variations in the gene encoding adeponectin receptor 1 (ADIPOR1) with body sin and insulin levels. The Finnish Diabetes Prevention Study. Diabetologia 49, 1795-1805 (2006).
66. Florez JC, Jablonski KA, Bayley N et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 355, 241-250 (2006).
67. Chiasson J-L, Josse RG, Gomis R et al. for the STOP-NIDDM Trial Research Group. Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359, 2072-2077 (2002).
68. Andrulionyte L, Zacharova J, Chiasson JL, Laakso M for the STOP-NIDDM Study Group. Common polymorphisms of the PPAR-γ2 (Pro12Ala) and PGC-1α (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to Type 2 diabetes in the STOP-NIDDM trial. Diabetologia 47, 2176-2184 (2004).
69. Zacharova, J, Chiasson JL, Laakso M for the STOP-NIDDM Study Group. The common polymorphisms (SNP +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to Type 2 diabetes: the STOP-NIDDM trial. Diabetes 54, 893-899 (2005).
70. Zacharova J, Todorova BR, Chiasson JL, Laakso M for the STOP-NIDDM Study Group. The G-250 substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to Type 2 diabetes: the STOP-NIDDM trial. J. Intern. Med. 257, 185-193 (2005).
71. Andruolionyte L, Chiasson J-L, Laakso M. SNPs of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from IGT to Type 2 diabetes: the STOP-NIDDM trial. Diabetes 55, 2148-2152 (2006).
72. Weyrich P, Stefan N, Häring H-U, Laakso M, Fritsche A. Effect of genotype on success of lifestyle intervention in subjects at risk for Type 2 diabetes. J. Mol. Med. 85, 107-117 (2007).
73. Nicklas BJ, van Rossum EF, Berman DM, Ryan AS, Dennis KE, Shuldiner AR. Genetic variation in the peroxisome proliferators-activated receptor-γ2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes 50, 2172-2176 (2001).
74. Kahara T, Takamura T, Hayakawa T et al. PPARγ gene polymorphism is associated with exercise-mediated changes of insulin resistance in healthy men. Metabolism 52, 209-212 (2003).
75. Weiss EP, Kulaputana O, Ghiu IA et al. Endurance training-induced changes in the insulin response to oral glucose are associated with the peroxisome proliferators-activated receptor-γ2 Pro12Ala genotype in men but not in women. Metabolism Clin. Exp. 54, 97-102 (2005).
76. Adamo KB, Sigal RJ, Williams K et al. Influence of Pro12Ala peroxisome proliferator-activated receptor γ2 polymorphism on glucose response to exercise training in Type 2 diabetes. Diabetologia 48, 1503-1509 (2005).
77. Sladek R, Rocheleau G, Rung J et al. A genome-wide association study identifies novel risk loci for Type 2 diabetes. Nature 445, 881-885 (2007).